The FDA has approved Tyvaso DPI (treprostinil) for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.
Related Keywords
Michael Benkowitz , Drug Administration , Chief Operating Officer ,
comparemela.com © 2020. All Rights Reserved.